R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition

被引:3
|
作者
Sears, Thomas K. [1 ]
Woolard, Kevin D. [2 ]
机构
[1] Northwestern Univ, Dept Neurol Surg, Chicago, IL 60611 USA
[2] UC Davis Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA USA
关键词
Mutant isocitrate dehydrogenase 1; 2 (IDH1; 2); Glioma; Bromodomain inhibition; Bromodomain and extraterminal (BET); JQ1; BRD4; PLURIPOTENCY; JQ1;
D O I
10.1007/s00432-022-04018-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Mutations in isocitrate dehydrogenase 1/2 (IDHmut) identify a subset of gliomas that exhibit epigenetic dysregulation via aberrant DNA methylation. These tumors are ultimately fatal and lack effective therapeutic strategies. Considering the epigenetic dysregulation of IDHmut gliomas, we hypothesized that epigenetic-targeting drugs may yield therapeutic benefits in gliomas bearing IDHmut. One set of targets includes the bromodomain and extraterminal (BET) family of transcriptional coactivators. Methods We used TCGA data from glioma patients to determine whether BET proteins affect patient survival differently based on IDH status. Follow-up experiments using a set of IDH wildtype/mutant glioma cultures, as well as an IDH wildtype glioblastoma cell line expressing exogenous R132H IDH1, focused on cell health assays to investigate whether IDHmut was associated with increased sensitivity to the BET inhibitor JQ1. Immunoblots were used to evaluate the molecular response to JQ1 in these cultures. Results We identified that high BRD4 expression associated with decreased survival only in IDHmut glioma patients. Cell viability analysis showed that IDHmut sensitized glioma cells to delayed cytotoxicity (10 days) in response to JQ1. Early effects of JQ1 (3 days) were primarily antiproliferative, with IDHmut glioma exhibiting a modest increase in sensitivity. Finally, exogenous R132H IDH1 expression in a resistant IDH wildtype cell line recapitulated the JQ1-mediated delayed cytotoxicity seen in our endogenous IDHmut glioma cells. Conclusion Overall, these data suggest that BRD4 enhances malignancy primarily in gliomas bearing IDHmut and is associated with greater sensitivity to BET inhibition. The finding that BET inhibition primarily exhibits delayed cytotoxicity may be overlooked in conventional short endpoint dose-response assays. Follow-up mechanistic and animal studies will help address the translational potential of these findings.
引用
收藏
页码:2275 / 2285
页数:11
相关论文
共 50 条
  • [1] R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition
    Thomas K. Sears
    Kevin D. Woolard
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2275 - 2285
  • [2] Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
    Pellegatta, Serena
    Valletta, Lorella
    Corbetta, Cristina
    Patane, Monica
    Zucca, Ileana
    Sirtori, Federico Riccardi
    Bruzzone, Maria Grazia
    Fogliatto, Gianpaolo
    Isacchi, Antonella
    Pollo, Bianca
    Finocchiaro, Gaetano
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2015, 3 : 4
  • [3] Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
    Serena Pellegatta
    Lorella Valletta
    Cristina Corbetta
    Monica Patanè
    Ileana Zucca
    Federico Riccardi Sirtori
    Maria Grazia Bruzzone
    Gianpaolo Fogliatto
    Antonella Isacchi
    Bianca Pollo
    Gaetano Finocchiaro
    Acta Neuropathologica Communications, 3
  • [4] In Situ Sprayed Starvation/Chemodynamic Therapeutic Gel for Post-Surgical Treatment of IDH1 (R132H) Glioma
    Li, Chunying
    Wan, Yilin
    Zhang, Yifan
    Fu, Lian-Hua
    Blum, Nicholas Thomas
    Cui, Run
    Wu, Boda
    Zheng, Rui
    Lin, Jing
    Li, Zhiming
    Huang, Peng
    ADVANCED MATERIALS, 2022, 34 (05)
  • [5] Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors
    Capper, David
    Weissert, Susanne
    Balss, Joerg
    Habel, Antje
    Meyer, Jochen
    Jaeger, Diana
    Ackermann, Ulrike
    Tessmer, Claudia
    Korshunov, Andrey
    Zentgraf, Hanswalter
    Hartmann, Christian
    von Deimling, Andreas
    BRAIN PATHOLOGY, 2010, 20 (01) : 245 - 254
  • [6] Somatic Mosaicism of IDH1 R132H Predisposes to Anaplastic Astrocytoma: A Case of Two Siblings
    Lee, Sulgi
    Kambhampati, Madhuri
    Almira-Suarez, M. Isabel
    Ho, Cheng-Ying
    Panditharatna, Eshini
    Berger, Seth, I
    Turner, Joyce
    Van Mater, David
    Kilburn, Lindsay
    Packer, Roger J.
    Myseros, John S.
    Vilain, Eric
    Nazarian, Javad
    Bornhorst, Miriam
    FRONTIERS IN ONCOLOGY, 2020, 9
  • [7] R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling
    Cui, Daming
    Ren, Jie
    Shi, Jinlong
    Feng, Lijing
    Wang, Ke
    Zeng, Tao
    Jin, Yi
    Gao, Liang
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2016, 73 : 72 - 81
  • [8] Gaining Insight into the Catalytic Mechanism of the R132H IDH1 Mutant: A Synergistic DFT Cluster and Experimental Investigation
    Broome, Joshua A.
    Nguyen, Nguyen P.
    Baumung, Cassidy R. E.
    Chen, Vincent C.
    Bushnell, Eric A. C.
    BIOCHEMISTRY, 2024, 63 (20) : 2682 - 2691
  • [9] Segregation of Non-p.R132H Mutations in IDH1 in Distinct Molecular Subtypes of Glioma
    Gravendeel, Lonneke A. M.
    Kloosterhof, Nanne K.
    Bralten, Linda B. C.
    van Marion, Ronald
    Dubbink, Hendrikus Jan
    Dinjens, Winand
    Bleeker, Fonnet E.
    Hoogenraad, Casper C.
    Michiels, Erna
    Kros, Johan M.
    van den Bent, Martin
    Smitt, Peter A. E. Sillevis
    French, Pim J.
    HUMAN MUTATION, 2010, 31 (03) : E1186 - E1199
  • [10] A Case of Ollier's Disease with P53 Mutation Positive and IDH1 (R132H) Negative Multicentric Gliomas
    Nishtha, Y.
    Maya, B.
    Shetty, Safal S.
    Ganaraj, V. H.
    Nupur, P.
    Yasha, T. C.
    Netravathi, M.
    NEUROLOGY INDIA, 2020, 68 (03) : 657 - 659